Pazopanib for the treatment of renal cell carcinoma

被引：16
|
作者：
Welsh, Sarah J. [1 ]
Fife, Kate [1 ]
机构：
[1] Cambridge Univ Hosp NHS Fdn Trust, Cambridge CB2 0QQ, England
来源：
FUTURE ONCOLOGY | 2015年 / 11卷 / 08期
关键词：
antiangiogenic; kidney; pazopanib; renal cancer; treatment; tyrosine kinase inhibitor; DOUBLE-BLIND; PHASE-III; TARGETED THERAPIES; SUNITINIB; SAFETY; EFFICACY; TRIAL;
D O I：
10.2217/fon.14.274
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The incidence and mortality from renal cell cancer (RCC) is increasing. RCC tumors are particularly vascular in nature as a result of disruption of the VHL gene and/or its upstream pathway leading to upregulation of the hypoxia-inducible factor transcription factor. The hypoxia-inducible factor pathway drives angiogenesis by upregulating VEGF and bFGF, amongst other proangiogenic downstream target genes. Therapies which target angiogenesis have been successful in treating metastatic RCC (mRCC) and the receptor tyrosine kinase inhibitor, pazopanib, is licensed for first line treatment of mRCC. This review details the past, current and future roles of pazopanib in the treatment of mRCC.
引用
收藏
页码：1169 / 1179
页数：11
相关论文
共 50 条
  • [31] Pazopanib: The newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma
    Keisner S.V.
    Shah S.R.
    Drugs, 2011, 71 (4) : 443 - 454
  • [32] Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
    Motzer, Robert J.
    Hutson, Thomas E.
    Cella, David
    Reeves, James
    Hawkins, Robert
    Guo, Jun
    Nathan, Paul
    Staehler, Michael
    de Souza, Paul
    Merchan, Jaime R.
    Boleti, Ekaterini
    Fife, Kate
    Jin, Jie
    Jones, Robert
    Uemura, Hirotsugu
    De Giorgi, Ugo
    Harmenberg, Ulrika
    Wang, Jinwan
    Sternberg, Cora N.
    Deen, Keith
    McCann, Lauren
    Hackshaw, Michelle D.
    Crescenzo, Rocco
    Pandite, Lini N.
    Choueiri, Toni K.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (08): : 722 - 731
  • [33] Is Pazopanib Safe and Efficacious in Patients with Metastatic Renal Cell Carcinoma?
    Ronald M. Bukowski
    Current Oncology Reports, 2010, 12 : 77 - 79
  • [34] Pazopanib-induced chylothorax in a patient with renal cell carcinoma
    Koylu, Bahadir
    Tekin, Fatih
    Aktas, Burak Yasin
    Kilickap, Saadettin
    Koksal, Deniz
    ANTI-CANCER DRUGS, 2022, 33 (01) : E555 - E557
  • [35] Tailoring treatment with cabozantinib or pazopanib in patients with metastatic renal cell carcinoma: does it affect outcome?
    Coriano, Matilde
    Giannarelli, Diana
    Scartabellati, Giulia
    De Giorgi, Ugo
    Brighi, Nicole
    Fornarini, Giuseppe
    Tommasi, Chiara
    Giudice, Giulia Claire
    Rebuzzi, Sara Elena
    Puglisi, Silvia
    Caffo, Orazio
    Kinspergher, Stefania
    Mennitto, Alessia
    Cattrini, Carlo
    Santoni, Matteo
    Verzoni, Elena
    Rametta, Alessandro
    Stellato, Marco
    Malgeri, Andrea
    Roviello, Giandomenico
    Brunelli, Matteo
    Signori, Alessio
    Banna, Giuseppe Luigi
    Buti, Sebastiano
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (05) : 545 - 554
  • [36] NICE guidance on pazopanib for first-line treatment of advanced renal-cell carcinoma
    Griffiths, Christian
    Hay, Nicola
    Sutcliffe, Frances
    Stevens, Andrew
    LANCET ONCOLOGY, 2011, 12 (03): : 221 - 222
  • [37] Modeling tumor growth kinetics after treatment with pazopanib or placebo in patients with renal cell carcinoma
    Peter L. Bonate
    A. Benjamin Suttle
    Cancer Chemotherapy and Pharmacology, 2013, 72 : 231 - 240
  • [38] Is Pazopanib Safe and Efficacious in Patients with Metastatic Renal Cell Carcinoma?
    Bukowski, Ronald M.
    CURRENT ONCOLOGY REPORTS, 2010, 12 (02) : 77 - 79
  • [39] Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma
    Hutson, Thomas E.
    Davis, Ian D.
    Machiels, Jean-Pascal H.
    De Souza, Paul L.
    Rottey, Sylvie
    Hong, Bao-fa
    Epstein, Richard J.
    Baker, Katherine L.
    McCann, Lauren
    Crofts, Theresa
    Pandite, Lini
    Figlin, Robert A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (03) : 475 - 480
  • [40] Pazopanib-induced enteritis in a patient with renal cell carcinoma
    Ariyoshi, Misa
    Hayashi, Ryohei
    Takasago, Takeshi
    Yamashita, Ken
    Hiyama, Yuichi
    Yuge, Ryo
    Urabe, Yuji
    Ueno, Yoshitaka
    Shimamoto, Fumio
    Oka, Shiro
    CLINICAL JOURNAL OF GASTROENTEROLOGY, 2024, 17 (03) : 434 - 440
12345